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 Mutant tumor antigens have recently emerged as major targets of endogenous 
tumor-specific T cells. Vaccination against these neoantigens therefore provides the 
opportunity to augment antitumor lymphocyte responses. In this context, we developed a 
technology to prime and expand desired populations of antigen-specific T cells based on 
programmed self-assembly of cognate peptide-MHC (pMHC). We capitalized on the 
unique properties of the protein annexin V (ANXA5) to couple the early onset of TCR 
signaling to stabilization of pMHC-TCR interactions, repeated pMHC encounter, and 
extensive TCR crosslinking. This system amplified lymphocyte activation by over 1,000-
fold, bypassed the need for costimulation, and overcame tolerance to a model self-antigen 
in vivo. These studies lay the foundation for immune modulation via a positive feedback-
driven self-assembly platform. Furthermore, we created a single-molecule imaging 
approach for quantitative and structural analysis of circulating mutant tumor proteins, 
which may ultimately be applied to identify tumor neoantigens. We demonstrated in 
preclinical models that mutant tumor proteins are released from tumor cells into the blood 
early in tumor progression. We then utilized this technology to profile circulating mutant 
p53 in ovarian cancer patients. Single-molecule structural analysis revealed that, in a subset 
of patients, circulating mutant p53 aggregates into complexes. Moreover, patients lacking 
circulating mutant p53 displayed abundant anti-p53 autoantibodies, suggesting that host 
immune responses clear mutant tumor antigens from the blood. Finally, we propose that 
structural analysis of circulating mutant tumor proteins by single-molecule imaging may 
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I. Chapter 1. An integrated paradigm of cancer immunotherapy 
and disease profiling. 
 
Introduction: a brief history of cancer immunotherapy. The original idea of 
invigorating the host immune system to combat cancer dates back to the work of Coley in 
the early 1900s1. Shortly afterwards, this concept was superseded in the clinical arena by 
prominent advances in chemotherapy and radiotherapy, though key insights into the 
relationship between cancer and the immune system continued to be uncovered in the 
laboratory. In the 1950s, Ehrlich, Burnet, and Thomas posited that the adaptive immune 
system constantly scans the body for and eliminates malignant cells2; as a corollary to this, 
cancer arises from defective immune surveillance. In the early 2000s, nearly a century since 
Coley, the theory of cancer immune editing was unveiled, portraying a dual role of the 
immune system in both promoting cancer in some instances and curbing its growth in 
others3. 
The discovery of the intricate interactions between cancer and the immune 
system—catalyzed by an explosion in the understanding of immune pathways and major 
advances in molecular biology—has fueled tremendous enthusiasm for leveraging the 
immune system to control cancer. 
Indeed, in recent years immunotherapy has raced to the forefront of novel 
interventions for cancer4. The discovery, for instance, that costimulatory signals are 
essential for full lymphocyte activation, and that CTLA-45 on T cells competes with CD28 
for B7 costimulatory signals on antigen-presenting cells6, thereby shutting down these T 
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cells, led to the use of antagonist CTLA-4 antibodies to augment antitumor immune 
responses, first in mice7 and then in melanoma patients8, 9. Similarly, antibodies that block 
a separate immune checkpoint pathway, the programmed death-1 (PD-1) receptor and its 
ligand (PD-L1)10, 11, have produced cancer regression in a substantial number of patients 
across a broad spectrum of cancer types, including melanoma, non-small cell lung cancer, 
colorectal cancer, and renal cell carcinoma12. Outside of checkpoint inhibitors, adoptive 
transfer of tumor-reactive T cells has also shown modest clinical success thus far13. For 
instance, Rosenberg and colleagues reported 50% partial or complete responses in 
melanoma patients treated by adoptive therapy14. In addition, in a study of adoptive therapy 
with chimeric antigen receptor-bearing T cells modified to recognize CD19 in acute 
lymphoblastic leukemia, complete remission was observed in 90% of patients15. 
Barriers to clinical success. Altogether, these clinical data underscore the potential 
of the immune system to control cancer. By harnessing the exquisitely specific, self-
propagating nature and long-term memory of T cells, immunotherapy offers the hope of 
lasting disease control16. However, T cells rarely clear tumor cells completely from the 
body. In fact, most patients undergoing immunotherapy still fail to mount any noticeable 
antitumor immune responses or eventually experience disease relapse16. 
Accumulating evidence indicates that tumor cells employ myriad mechanisms to 
evade host immune defenses, including: downregulation of MHC class I, b2 microglobulin, 
or antigen-processing machinery16, 17; production of inhibitory enzymes (e.g., IDO, 
arginase) or cytokines (e.g., IL-10, TGF-b)18; recruitment of suppressive subsets of cells 
(e.g., regulatory T cells, immature myeloid cells)19-24; gain of survival factors16; and 
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elaboration of checkpoint molecules (e.g., PD-L1, CTLA-4), which turn off tumor-specific 
T cells25. 
In light of these many immune escape mechanisms and the diversity of immune 
responses seen in patients, it is important to explore the key determinants of durable 
antitumor responses. Vigorous efforts are currently underway to dissect the mechanisms 
that underlie durable responses—or lack thereof—to immunotherapy. 
The tumor microenvironment as a permissive site for launching tumor-specific 
immune responses. One central idea is that—although tumor cells have been sculpted 
through the process of immune editing26—through the expression of unique mutant or 
ectopic antigens, the tumor has a natural tendency to provoke antitumor immune responses, 
and the number of pre-existing functional tumor-specific lymphocyte precursors may 
govern both disease outcome and responses to therapy. In a landmark study, Galon et al. 
established that the abundance of T cells within tumor tissue strongly predicts prognosis, 
even more so than conventional TNM staging27. Likewise, in cervical cancer patients, a 
high density of CD8+ T cells in the tumor correlated with absence of metastasis and 
prolonged survival28, 29. These results indicate that the immune system is on its own capable 
of mounting cytotoxic responses against tumor cells, and the magnitude of these responses 
dictates to a large extent disease outcome. In our own work, we found that antigen exposure 
within the tumor—as occurs following chemotherapy—stimulates tumor-specific CD8+ T 
cells via the type I IFN pathway30. Consistent with this, clinical responses to PD-1 blockade 
depended on the presence of pre-existing CD8+ T cells in the tumor vicinity31. Collectively, 
these data argue that the availability of endogenous tumor-specific lymphocyte precursors 
is a critical determinant of antitumor immune responses. It is therefore essential develop 
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strategies to firstly identify and secondly amplify dormant populations of these lymphocyte 
precursors. 
The emerging landscape of tumor neoantigens. The activation and expansion of 
rare tumor-specific lymphocyte populations first requires uncovering the antigens against 
which they react. The clinical progress that has been achieved by checkpoint blockade 
therapy, together with technical advances in whole-exome sequencing, has provided the 
opportunity to investigate the cognate antigens of tumor-specific T cells. For example, 
Gubin et al. found through bioinformatics techniques in preclinical sarcoma models that 
these T cells predominately recognize mutant antigens32. Consistent with this, in cancer 
patients, clinical benefit is associated with an extensive load of mutant tumor proteins33, 34, 
specific mutant neoepitopes35, 36, and DNA mismatch repair defects37. Together, these 
results imply that host T cells efficiently spot mutant antigens displayed by tumor cells. 
Capitalizing on this idea, in a proof-of-principle study, Kreiter et al. designed peptides 
against mutant antigens and demonstrated tumor rejection in preclinical models38. 
Approaches to generate T cells against mutant tumor are therefore likely to elicit 
durable antitumor immune responses. Though neoantigens are in principle unique to tumor 
cells and hence less susceptible to central tolerance than tumor-associated antigens39, 
neoantigens may nonetheless exhibit weak affinity for cognate TCR, as is almost 
universally the case of self-antigens. To address this challenge, we introduce a novel 
vaccination technology based on programmed self-assembly of peptide-MHC (pMHC). 
This technology opens the opportunity to amplify endogenous lymphocyte responses to 
mutant tumor antigens. 
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Early detection and disease profiling as critical elements of effective 
immunotherapy. Although immunotherapy has transformed the landscape of cancer 
management, this type of therapy is likely most effective for early-stage disease, while the 
tumor has not yet grown beyond the capacity of T cells to control it. As the tumor expands, 
immune-suppressive networks thrive and nutrients are depleted, rendering the tumor 
microenvironment inhospitable for infiltrating T cells. Indeed, it is well-established that 
early cancer detection and intervention improves clinical outcome. For instance, cancer 
morbidity and mortality occurs commonly due to late disease diagnosis, and epidemiologic 
data illustrate that the most lethal cancer types, such as ovarian or pancreatic cancer, are 
also those which are hardest to identify. Thus, vaccination against mutant tumor antigens 
holds the greatest probability of success early in the course of disease, highlighting the 
urgent need for advances in cancer detection. Furthermore, accurate, rapid profiling of 
mutant tumor antigens is equally important to identify suitable candidates for vaccination. 
Conventional assays for tumor proteins, such as those that screen for CA-125 (in 
ovarian cancer) or PSA (in prostate cancer), lack the sensitivity and specificity demanded 
for reliable early cancer detection and cannot be applied for profiling mutant tumor 
antigens40-44. The concept of ‘liquid biopsies’, revolving around the detection of circulating 
tumor DNA via next-generation sequencing, has recently shown promise45. However, 
while these approaches have improved dramatically from a technical standpoint in recent 
years45, they still miss the disease in approximately 50% of patients with stage I or II 
cancer46. Furthermore, circulating tumor DNA does not provide information about gene 
expression within the tumor, or about the structural or functional features of altered 
oncoproteins and tumor suppressor proteins. 
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To address the need for early cancer detection and profiling methods, we invented 
a single-molecule imaging technology to identify circulating mutant tumor proteins, as well 
as autoantibodies to these proteins. By imaging these mutant proteins at single-molecule 
resolution, we can deduce their structural and functional properties, a feat that cannot be 
attained by other methods. We foresee that this imaging platform may be utilized to: (1) 
identify the presence of cancer and (2) characterize mutant antigens amenable to 
immunotherapy. 
New technologies for cancer immunotherapy and disease profiling. In Chapter 
2, we build on the compelling idea that tumor neoantigens can be targeted via rational 
vaccination strategies to amplify antigen-specific lymphocyte responses. We present a 
programmable vaccination approach to engineer signaling events at the level of pMHC-
TCR interactions to—in a concerted manner—stabilize pMHC-TCR binding, facilitate 
serial pMHC encounter, and induce TCR crosslinking. We demonstrate that this 
technology markedly augments lymphocyte activation and overcomes immune tolerance 
to low-affinity antigens, which may be useful in raising responses against mutant tumor 
proteins. 
In Chapter 3, we present a single-molecule imaging approach to identify mutant 
tumor proteins early—at a stage in which the disease has a high chance of being 
successfully managed by immunotherapy—and to characterize its structural and functional 
features. We believe that this approach offers the potential to catch cancer early and to 
pinpoint the characteristics of the tumor most amenable to therapy. 
Finally, in Chapter 4, we lay out our vision for how these technologies can be 
integrated to build a comprehensive next-generation immunotherapy platform. We propose 
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that single-molecule imaging can serve as a powerful tool to simultaneously identify and 
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II. Chapter 2. Programmed self-assembly of peptide-MHC for 
antigen-specific immune modulation 
 
A technology to prime any desired population of T cells in the body—
particularly those that possess low avidity against target antigen—would pave the 
way to the design of new types of vaccination for intractable infectious diseases or 
cancer. Here we report such a technology based on positive feedback-driven, 
programmed self-assembly of peptide-MHC (pMHC) directly on the membrane of 
cognate T cells. Our design capitalizes on the unique features of the protein annexin 
V (ANXA5), which—in a concerted and synergistic manner—couples the early onset 
of TCR signaling by cognate pMHC with a surge in pMHC-TCR affinity, with 
repeated pMHC encounter, and with widespread TCR crosslinking. In our system, 
ANXA5 is linked to pMHC and firmly engages the plasma membrane of cognate T 
cells upon (and only upon) the early onset of TCR signaling. ANXA5 in turn exerts a 
mechanical force that stabilizes interactions at the TCR-pMHC interface and 
facilitates repeated, serial pMHC encounter. Furthermore, ANXA5 quickly arranges 
into uniform 2D matrices, thereby prompting TCR crosslinking. Fusion of ANXA5 to 
pMHC augments lymphocyte activation by several orders of magnitude (>1,000-fold), 
bypasses the need for costimulation, and breaks tolerance against a model self-antigen 
in vivo. Our study opens the door to the application of synthetic, feedback-driven self-
assembly platforms in immune modulation. 
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Due to their unique capacity to recognize a nearly infinite array of antigen variants 
with exquisite sensitivity, T cells have the potential to eradicate many types of diseases, 
from those caused by external pathogens to those caused by transformation from within 
(i.e. cancer). In many instances, however, activation of a desired population of T cells by 
vaccination remains an elusive challenge. For example, in the case of cancer, although it 
has been shown that T cells can play a key role in the control of tumor progression1-5, 
tumor-specific T cells almost universally suffer from a poor capacity to recognize tumor 
antigen due to intricate mechanisms of central and peripheral immune tolerance6, 7. We 
thought that activation and expansion of any desired population of T cells could be 
achieved by precisely engineering the cascade of molecular events at the level of 
interactions between the TCR and cognate peptide-MHC (pMHC), as this is a major control 
point for the ultimate fate of T cells. In particular, it has been established that the avidity 
of T cells for their target antigen is dictated by the affinity8-10, frequency11-13, and valency14, 
15 of interactions between TCR and cognate pMHC. In fact, in order for T cells to undergo 
full activation and expansion in response to antigen encounter, they must exhibit a high 
TCR affinity for cognate pMHC (‘kinetic proofreading’ model)8-10, sample the antigen 
persistently (‘serial triggering’ model)11-13, or acquire high TCR occupancy by pMHC 
(‘valency’ model)14, 15. 
We reasoned that the simultaneous fulfillment of all these criteria would pave the 
way to the activation of low avidity T cells. We further deduced that high TCR affinity 
could be realized by imposing a mechanical force at the molecular level to stabilize 
interactions with cognate pMHC (analogous to a super-antigen), that serial TCR triggering 
would occur if cognate pMHC was held in the vicinity of TCR, and that high TCR 
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occupancy could be attained by extensive TCR crosslinking. In conjunction, these events 
would synergistically amplify signaling through the TCR, resulting in the robust activation 
of even low avidity T cells. 
Here we report a technology to accomplish this based on programmed self-
assembly of pMHC on the membrane of cognate T cells. We constructed a system in which 
a ‘dynamic anchor’ couples the early onset of TCR signaling by cognate pMHC with a 
surge in pMHC-TCR affinity, with repeated pMHC encounter, and with widespread TCR 
crosslinking. To achieve this, we programmed the dynamic anchor to sense and react to 
certain microenvironmental cues. In particular, the dynamic anchor: (1) exclusively 
recognizes antigen-specific T cells in a positive feedback-driven process catalyzed by the 
onset of TCR signaling, (2) attaches tightly to the membrane of these T cells, and (3) 
undergoes rapid self-assembly upon binding to the membrane. Our design incorporates the 
protein annexin V (ANXA5) as a dynamic anchor and exploits several unique features of 
this protein and its phospholipid receptor, phosphatidylserine (PS). First, ANXA5 has a 
high affinity for PS (KD~10-10 M) under physiologic calcium concentrations. Second, we 
have mapped the kinetics of PS exposure on T cells and found that PS is externalized 
rapidly and reversibly in cognate T cells upon TCR signaling by pMHC. And third, 
ANXA5 is equipped with the remarkable capacity to organize into uniform 2D matrices on 
the lipid bilayer16. 
We demonstrated that programmed pMHC self-assembly on cognate T cells via the 
ANXA5 anchor augments antigen-specific lymphocyte activation by over 1,000-fold, 
bypasses the need for costimulation, and reverses tolerance to self-antigen. We investigated 
the mechanisms underlying these effects and discovered that ANXA5 fusion overrides low-
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affinity pMHC-TCR interactions. Both pMHC tethering and self-assembly by ANXA5 
were found to be critical for immune modulation. Furthermore, downstream of initial 
pMHC encounter, this system instigated TCR crosslinking and internalization. Our results 
introduce the concept of programmed pMHC self-assembly as a vaccination approach for 
amplifying lymphocyte responses against low-affinity antigen, such as tumor antigen. 
 
Results 
Design and validation of the chimeric ANXA5-pMHC system. We constructed 
a system in which a ‘dynamic anchor’ couples the early onset of TCR signaling by cognate 
pMHC with a surge in pMHC-TCR affinity, with repeated pMHC encounter, and with 
widespread TCR crosslinking (Figure II-1a, b). To achieve this, we programmed the 
dynamic anchor to sense and react to certain microenvironmental cues. In particular, the 
dynamic anchor (1) exclusively recognizes antigen-specific T cells in a positive feedback-
driven process catalyzed by the onset of TCR signaling, (2) attaches tightly to the 
membrane of these T cells, and (3) undergoes rapid self-assembly upon binding to the 
membrane. Our design incorporates the protein ANXA5 as a dynamic anchor and exploits 
several unique features of this protein and its phospholipid receptor, phosphatidylserine 
(PS). First, ANXA5 has a high affinity for PS (KD~10-10 M) under physiologic calcium 
concentrations. Second, we have mapped the kinetics of PS exposure on T cells and found 
that PS externalizes rapidly and reversibly in cognate T cells upon TCR signaling by 
pMHC (Figure II-2a), with peak PS exposure at ~12 hr followed by full translocation to 
the inner membrane by 72 hr (Figure II-2b). PS exposure also occurred on naïve T cells 
ex vivo in response to CD3 crosslinking (Figure II-2c), as close to 80% of stimulated T 
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cells converted to surface PS+ after 12 hr (Figure II-2d). And third, ANXA5 is equipped 
with the remarkable capacity to organize into uniform 2D matrices on the lipid bilayer16. 
As proof-of-concept, we synthesized a recombinant soluble single-chain pMHC 
(hereafter referred to as Kb(Ova)) composed of the model H-2Kb-restricted ovalbumin 
(Ova) epitope (SIINFEKL) linked to b2M and H-2Kb heavy chain carrying deletions in the 
transmembrane domain and cytoplasmic tail. We then linked the α3 domain of H-2Kb 
heavy chain in Kb(Ova) to ANXA5 to create chimeric Kb(Ova)/ANXA5 (Figure II-1b). 
To verify pMHC display by the chimeric protein, we incorporated a polyhistidine (His) tag 
at the C-terminus and synthesized liposomes embedded with nitrilotriacetic acid-nickel 
(NTA-Ni). We coated Kb(Ova)/ANXA5 or its counterpart control, Kb(Ova), onto NTA-
Ni liposomes and probed with antibodies against H-2Kb/SIINFEKL. We determined by 
flow cytometry that Kb(Ova) and Kb(Ova)/ANXA5 displays similar amounts of H-
2Kb/SIINFEKL at >10-fold above background levels (Supplementary Figure II-1a, b). 
Thus, we conclude that fusion to ANXA5 maintains pMHC in an intact state, and effects 
of the chimeric protein are independent of native pMHC conformation. Next, we confirmed 
that pMHC/ANXA5 associates with PS phospholipid bilayers. To do so, we synthesized 
PS+ liposomes to mimic the lymphocyte plasma membrane, pulsed the liposomes with 
Kb(Ova)/ANXA5 or Kb(Ova) for 30 min, and probed with H-2Kb/SIINFEKL antibodies. 
PS+ liposomes pulsed with pMHC/ANXA5 displayed 40 times more pMHC than those 
pulsed with pMHC only (Supplementary Figure II-2a, b), indicating that ANXA5 
mediates pMHC binding to PS lipid bilayers. Both Kb(Ova)/ANXA5 and Kb(Ova) failed 
to attach to PS- liposomes (data not shown). Therefore, we conclude that chimeric 
pMHC/ANXA5 interacts with and presents antigen on a PS surface. 
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pMHC fusion to ANXA5 augments cognate lymphocyte activation. Since PS 
exposure is a feature of apoptosis, we first assessed the survival of T cells in the presence 
of pMHC/ANXA5 to exclude the potential influence of apoptosis on the behavior of this 
chimeric protein. T cells treated with Kb(Ova)/ANXA5, ANXA5, Kb(Ova), or no protein 
demonstrated almost identical viability (~90%) (Supplementary Figure II-3a, b), 
verifying that Kb(Ova)/ANXA5 does not induce lymphocyte apoptosis. To test the 
function of the pMHC/ANXA5 system, we incubated resting Ova-specific CD8+ T cells 
(OT-I) with Kb(Ova) or Kb(Ova)/ANXA5 (2.5 µg/ml) and performed flow cytometry after 
12 hr to detect IFN-γ expression as an index of activation. At this dose, Kb(Ova)/ANXA5 
produced >80% IFN-g+ T cells, while Kb(Ova) produced <2% IFN-g+ T cells (Figure II-
3a, b). Protein titration experiments demonstrated that pMHC/ANXA5 was >1,000´ more 
potent than monomeric pMHC in lymphocyte activation, as defined by the minimal dose 
of antigen required to detect IFN-g+ cells (Figure II-3c). Notably, Kb(Ova)/ANXA5—but 
not Kb(Ova)—also induced robust activation of naïve Ova-specific T cells freshly isolated 
from OT-I transgenic mice without any costimulation (Figure II-3d). Cognate lymphocyte 
activation upon Kb(Ova)/ANXA5 exposure was accompanied by proliferation (Figure II-
3e). Since it has been shown that activation of T cells by dimeric pMHC is superior to 
activation by monomeric pMHC17, we compared activation of T cells by pMHC/ANXA5 
versus dimeric pMHC/Fc. Kb(Ova)/ANXA5 was >100´ more potent than Kb(Ova)/Fc 
(Supplementary Figure II-4a-c). Moreover, Kb(Ova)/ANXA5 did not elicit IFN-γ 
expression in non-cognate T cells even at high dose (>10 µg/ml) (data not shown), 
confirming that activation of T cells by pMHC/ANXA5 is antigen-specific.  
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We inferred that ANXA5-driven programmed pMHC self-assembly may trigger 
antigen-specific lymphocyte responses in vivo. To test this, we first administered either 
Kb(Ova)/ANXA5 or Kb(Ova) into OT-I TCR transgenic mice. After one day, we measured 
CD69 expression on CD8+ T cells as a marker of early activation. ~40% of CD8+ T cells 
in Kb(Ova)/ANXA5-administered mice displayed surface CD69, compared to <2% in 
Kb(Ova)-administered mice (Figure II-4a), suggesting that Kb(Ova)/ANXA5 rapidly 
induces in vivo lymphocyte activation even in the absence of costimulation. In C57BL/6 
mice with a diverse lymphocyte TCR repertoire, Kb(Ova)/ANXA5 amplified Ova-specific 
CD8+ T cells (Figure II-4b), indicating that pMHC fusion to ANXA5 expands rare cognate 
lymphocyte precursors. Consistently, Kb(Ova)/ANXA5 injection led to proliferation of 
naïve Ova-specific T cells in vivo, at ~100-fold lower dose than Kb(Ova) (Figure II-4c, 
Supplementary Figure II-5). 
By stabilizing low-affinity pMHC-TCR interactions, we reasoned that ANXA5 
fusion might overcome immune tolerance to self-antigen. To test this, we employed 
transgenic mice (232-4) that exhibit ectopic expression of Ova in the intestine18. In this 
model, Ova serves as a self-antigen; therefore, endogenous CD8+ T cells in 232-4 
transgenic mice possess tolerance to Ova, and Ova-specific CD8+ T cells cannot be elicited 
in these mice by conventional methods. Intriguingly, we found that an Ova-specific 
immune response emerged in 232-4 transgenic mice administered with Kb(Ova)/ANXA5 
but not with Kb(Ova) (Figure II-4d), suggesting that this technology is able to break 
immune tolerance to self-antigen. 
ANXA5 fusion overcomes low-affinity pMHC-TCR interactions. We wondered 
whether loss of tolerance to self-antigen might be due to the capacity of the dynamic anchor 
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to override low-affinity pMHC-TCR interactions. We observed that naïve OT-I cells 
treated with monomeric Kb(Ova) protein exposed surface PS (Figure II-5a), implying that 
weak pMHC-TCR interactions are sufficient to trigger PS membrane translocation, which 
propagates pMHC/ANXA5 self-assembly. To directly test the effect of low affinity 
pMHC-TCR binding on lymphocyte activation, we synthesized a panel of 
Kb(Ova)/ANXA5 variants with altered peptide ligands (APLs) carrying critical single 
amino acid substitutions in the Ova epitope that markedly diminish the affinity for TCR 
(but not for H-2Kb)19. We found that when linked to ANXA5, these APLs could induce 
robust activation of OT-I cells, far superior to the Kb(Ova) control carrying the wildtype 
SIINFEKL epitope (Figure II-5b). Furthermore, the increase in amount of peptide needed 
to compensate for affinity-dampening mutations in the Ova antigen greatly exceeded the 
corresponding amount of Kb(Ova) needed (Figure II-5c). These results suggest that fusion 
to ANXA5 overcomes low-affinity pMHC-TCR interactions, bolstering activation of 
cognate T cells by several orders of magnitude and bypassing the need for costimulation. 
Molecular mechanisms underlying lymphocyte activation by pMHC/ANXA5. 
We reasoned that fusion of ANXA5 to pMHC would tether the pMHC to T cells upon TCR 
signaling in a positive feedback-driven process (Figure II-1a). Thus, chimeric 
pMHC/ANXA5 would exhibit both a high affinity and frequency of binding to cognate T 
cells. Consistent with this paradigm, the combined presence of pMHC and ANXA5 lacking 
a covalent linkage failed to stimulate cognate T cells (Supplementary Figure II-6). 
Moreover, excess soluble ANXA5 could not prevent lymphocyte activation by 
Kb(Ova)/ANXA5 (Supplementary Figure II-7), potentially due to high affinity 
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attachment of pMHC/ANXA5 to PS externalized upon local TCR membrane signaling, 
which was not outcompeted by ANXA5. 
We employed genetic, biochemical, and functional assays to dissect the 
mechanisms by which pMHC/ANXA5 operates. As ANXA5 binding to PS requires 
calcium, we measured lymphocyte activation by pMHC/ANXA5 under different calcium 
concentrations. Depleting calcium to 33% of physiologic levels impaired OT-I activation 
by >10-fold, demonstrating strict calcium dependence of pMHC/ANXA5 (Figure II-6a). 
To prove that this calcium dependence traces to disrupted ANXA5 membrane tethering, 
we synthesized two mutant versions of Kb(Ova)/ANXA5 carrying amino acid substitutions 
in the calcium-binding domain of ANXA5 (D144N, E228Q or D144N, E228Q, D303N) 
which abolish interactions between ANXA5 and PS20. We confirmed that these mutant 
proteins could display intact SIINFEKL peptide in the context of H-2Kb but failed to 
associate with PS (data not shown). Activation of OT-I cells by mutant Kb(Ova)/ANXA5 
proteins was severely impaired compared to wildtype Kb(Ova)/ANXA5 (Figure II-6b). 
Next, we examined the role of self-assembly in the immune-modulating function of 
ANXA5. To do so, we synthesized a mutant Kb(Ova)/ANXA5 carrying five different 
amino acid substitutions (R16E, R23E, K27E, K56E, K191E) which prevent self-assembly 
of ANXA521. We found likewise that loss of self-assembly ability abrogated the capacity 
of this mutant Kb(Ova)/ANXA5 to stimulate OT-I cells (Figure II-6c). Thus, we conclude 
that—in addition to membrane tethering—instigation of TCR crosslinking by the dynamic 
anchor is crucial for its ability to evoke lymphocyte activation. 
To directly investigate the role of the dynamic anchor in fastening pMHC to the 
membrane and triggering TCR signaling, we pre-mixed versions of Kb(Ova) or 
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Kb(Ova)/ANXA5 carrying a His tag with PE-labeled α-His mAb. We then incubated the 
proteins with OT-I cells at 37°C for 5 hr, and measured pMHC binding and TCR (Va2) 
expression by flow cytometry. We found that 98% of OT-I cells incubated with 
Kb(Ova)/ANXA5:a-His/PE complex became pMHC+ (i.e. displayed PE fluorescence); by 
contrast, <1% of OT-I cells incubated with Kb(Ova):a-His/PE or with a-His/PE only 
displayed PE fluorescence (Figure II-7a). Moreover, we noticed that—compared to the a-
His/PE control—TCR Va2 expression was downregulated by 90% of OT-I cells incubated 
with Kb(Ova)/ANXA5:a-His/PE but not by any of those cells incubated with Kb(Ova):a-
His/PE (Figure II-7a). The TCR is downregulated in T cells as a consequence of TCR 
engagement by cognate pMHC22. Based on these data, we conclude that pMHC/ANXA5 
acts on T cells to facilitate repeated, serial encounter with cognate TCR. 
To visualize the dynamic anchor-mediated tethering and self-assembly of pMHC 
on cognate T cells, we incubated Kb(Ova)/ANXA5:a-His/PE or Kb(Ova):a-His/PE with 
OT-I cells seeded at ultra-low density to prevent any cells from contacting each other and 
presenting pMHC in trans. We then examined individual T cells by epifluorescence single-
molecule microscopy to detect (1) total fluorescence as an index of pMHC binding and (2) 
fluorescence aggregation as an index of pMHC self-assembly. We found that while OT-I 
cells incubated with α-His/PE or Kb(Ova):α-His/PE displayed extremely low fluorescence, 
cells incubated with Kb(Ova)/ANXA5:α-His/PE displayed strong fluorescence which 
tightly clustered at distinct foci (Figure II-7b). These data demonstrate the engagement 
and self-assembly of dynamic anchor-linked pMHC on cognate T cells in cis, after which 





The programmed self-assembly of pMHC we have described represents a powerful 
approach for the activation of antigen-specific T cells, in particular those that have low 
affinity for cognate antigen. This approach would be useful for galvanizing a robust 
immune response against any low avidity tumor or virus antigen. In the field of cancer 
immunotherapy, ANXA5 fusion to soluble pMHC overcomes two major obstacles faced 
by vaccination: immune tolerance to tumor self-antigen and the need for functional 
antigen-presenting cells (APCs) and co-stimulation23, 24. With respect to immune self-
tolerance, we demonstrated that chimeric pMHC/ANXA5 could stabilize pMHC binding, 
facilitate repeated TCR encounters, and thereby override low-affinity pMHC-TCR 
interactions. This strategy is therefore suitable for priming and propagating low avidity 
endogenous lymphocyte precursors within the tumor. Furthermore, the tumor milieu 
elaborates a variety of immune-suppressive networks that either deplete or impair the 
function of APCs, such as dendritic cells25. Since conventional vaccination methods rely 
on a robust pool of APCs to display antigen to cognate T cells26, these methods are largely 
unreliable in the tumor microenvironment. By contrast, soluble, chimeric pMHC/ANXA5 
proteins directly target and prime antigen-specific T cells independent of APCs. Indeed, 
we discovered that infusion of these proteins alone could mediate activation of cognate 
naïve T cells both in vitro and within 24 hr post-delivery in vivo. Because the dynamic 
anchor bypasses the need for APCs, this approach is in principle less susceptible to immune 




It is generally believed that full lymphocyte activation requires not only peptide 
antigen display on MHC proteins but also co-stimulation from proteins such as CD80 and 
CD86 on APCs, which signal through CD28 on cognate T cells24. In this context, it is 
intriguing that ANXA5 fusion to pMHC circumvents the need for co-stimulation. Although 
the precise mechanisms for this are unclear, we propose that exponential amplification of 
total TCR signal strength by ANXA5 pushes T cells past the activation barrier even in the 
absence of co-stimulation. Consistent with this idea, it has previously been demonstrated 
that once TCR signal strength reaches a critical threshold, lymphocyte activation occurs 
regardless of co-stimulation27. 
The proof-of-concept experiments conducted here establish the application of 
positive feedback driven, self-assembly networks to trigger antigen-specific immune 
responses. The identification of appropriate tumor antigen candidates will be an important 
next step in clinical translation. Recent studies employing whole genome sequencing and 
tumor epitope profiling have revealed that antitumor lymphocyte responses are biased 
against mutant tumor proteins13, 28-32. In this light, we envision that ANXA5 may be linked 
to mutant antigen peptides on MHC proteins to prime and expand these endogenous tumor-
specific T cells. As epitope screening and profiling technologies advance, the ability to 
quickly raise immune responses against promising antigen candidates becomes critical. We 
believe the dynamic anchor concept introduced here provides a powerful tool for 
accomplishing this. Although in our we linked the antigen to a single-chain MHC/ANXA5 
molecule via genetic engineering, we foresee that a generic ‘empty’ MHC/ANXA5 
scaffold designed to the MHC haplotype of individual patients could be constructed that 
may be readily conjugated with any desired epitope of interest via chemical crosslinking. 
26 
	
This could lead to a versatile platform for antigen-specific immune modulation that could 
be rapidly tailored for different patients. 
Moreover, though our approach acts through mechanisms distinct from immune 
checkpoint blockade, we believe these two types of therapy will be synergistic when 
administered in combination. In particular, chimeric pMHC/ANXA5 proteins are devised 
to generate and expand desired populations of antigen-specific T cells, while checkpoint 
blockade potentiates the function of these T cells by dampening immune suppressive 
pathways33. The synergistic combination of checkpoint blockade with dynamic anchor-
based vaccination holds the potential to improve the clinical management of cancer. 
An additional important point to address in clinical translation involves the 
spectrum of target cells that might be recognized by pMHC/ANXA5, as well as the 
potential regions in the body to which these proteins would traffic. It is well-established, 
for instance, that apoptotic cells expose surface PS; consequently, a proportion of 
administered pMHC/ANXA5 would be anticipated to accumulate in injured, infected, or 
dead tissue. In cancer patients, a substantial amount of pMHC/ANXA5 would likely build 
up directly in the tumor, as subsets of tumor cells as well as tumor-associated endothelial 
cells externalize PS34-36. In our experiments, we have observed that following systemic 
injection into tumor-bearing mice, labeled ANXA5 proteins preferentially home to the 
tumor. In cancer immunotherapy, we believe that the selective delivery of pMHC/ANXA5 
represents an advantage of this system, as studies have reported that the presence of tumor-
infiltrating T cells is especially important for control of tumor growth1, 37. By binding to 
surface PS on these T cells, pMHC/ANXA5 provides a route to invigorate these local 
antitumor immune responses. 
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Finally, this approach can be tailored to precisely control the function of antigen-
specific T cells in a variety of other ways because the dynamic anchor-pMHC can be 
readily linked to additional ‘cargo’ modules. For example, cytokines could be delivered 
through this technology to amplify the expansion phase of a desired immune response. On 
the other hand, tolerance-promoting cues could be delivered to repress an autoimmune 
response. These targeted modalities are in principle far superior—both in terms of safety 
and efficacy—to conventional methods based on systemic injection of cytokines or other 
pharmacologic agents because, in this case, the cargo is directed preferentially to an 
antigen-specific compartment. Furthermore, the general concept of programmed molecular 
self-assembly could be applied to control other arms of the immune system. For instance, 
it has been shown that live B cells also expose surface PS in the vicinity of the BCR upon 
receiving an activation signal38, 39. Thus, the dynamic anchor technology could be deployed 
to raise a strong antibody response against intractable pathogens. We foresee that positive 
feedback-driven programmed molecular self-assembly will open the doors to the design of 
new, creative ways to both study and manipulate biological systems. 
 
Methods 
Mice. 6- to 8-week old female C57BL/6, OT-I TCR transgenic, and 232-4 
transgenic mice were obtained from the National Cancer Institute. All animal procedures 
complied with protocols approved by the Johns Hopkins Institutional Animal Care and Use 
Committee and with recommendations for the proper use and care of laboratory mice. 
Cells. Resting and naïve Ova-specific CD8+ T cells (OT-I) harvested from spleens 
of OT-I transgenic mice were employed. Cells were passaged weekly at 1:4 dilution and 
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stimulated with irradiated tumor cells (TC-1) pre-pulsed with Ova epitope (SIINFEKL). T 
cells were cultured in RPMI-1640 medium supplemented with 10% FBS. 
Synthesis and purification of pMHC/ANXA5. The Kb(Ova)/ANXA5 protein is 
composed of the mouse b2 microglobulin signal peptide at the N-terminus, SIINFEKL 
epitope, (GGGGS)3 linker, mouse b2 microglobulin, (GGGGS)4 linker, and the a1, a2, a3 
H-2Kb heavy chain, followed by ANXA5. A 6´ polyhistidine (his) tag was appended at the 
C-terminus to facilitate protein purification. The Kb(Ova) protein is identical to 
Kb(Ova)/ANXA5 except that it lacks the ANXA5 component. Plasmids encoding 
Kb(Ova)/ANXA5 or Kb(Ova) were generated by recombinant DNA technology and 
verified by DNA sequencing. Plasmids were transfected into suspension 293T cells; the 
encoded protein was subsequently purified by affinity chromatography on a nickel column 
and eluted with imidazole. Protein was then dialyzed and reconstituted in PBS. Protein 
integrity and purity were confirmed by SDS-PAGE. The predicted molecular weights of 
Kb(Ova)/ANXA5 and Kb(Ova) are 84 kD and 49 kD, respectively. 
Verification of pMHC/ANXA5 protein. Liposomes of ~1 µm diameter containing 
nickel-NTA or PS were synthesized by lipid film hydration and membrane extrusion. To 
test pMHC display, Kb(Ova)/ANXA5 or Kb(Ova) protein (1 µg) was conjugated to nickel-
NTA liposomes via the his tag and stained with PE-labeled a-H-2Kb/SIINFEKL antibody. 
Liposomes were examined by flow cytometry, with average PE fluorescence serving as an 
index of pMHC display. To test ANXA5 binding, Kb(Ova)/ANXA5 or Kb(Ova) protein 
(1 µg) was added to PS liposomes, stained with PE-labeled a-H-2Kb/SIINFEKL antibody, 
and interrogated by flow cytometry as described above. 
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Characterization of PS exposure on T cells. For in vitro experiments, resting OT-
I T cells were incubated with SIINFEKL-loaded TC-1 feeder cells (1:1 ratio) for 72 hr. At 
12, 24, 48, and 72 hr, cells were harvested, stained with FITC-labeled ANXA5, and 
examined by flow cytometry. The percentage of ANXA5+ cells, as well as mean ANXA5 
binding intensity, were ascertained. To test PS exposure in response to weak antigen 
stimuli, resting OT-I cells were treated with monomeric Kb(Ova) protein or Ova peptide 
(1 µg/ml), and ANXA5 binding was measured as described above. For ex vivo experiments, 
naïve splenocytes were extracted from C57BL/6 mice and pulsed overnight with plate-
coated a-CD3 antibody (1 µg/ml). Cells were stained with fluorophore-labeled a-CD8 and 
a-CD69 antibody, as well as FITC-labeled ANXA5. Lymphocyte activation and ANXA5 
binding were determined by flow cytometry as described above. 
Characterization of lymphocyte activation. For in vitro experiments, T cells were 
seeded in 96-well plates at 104 cells/well and incubated with pMHC/ANXA5 in the 
presence of brefeldin A. After 12 hr, cells were harvested, stained for CD8, permeabilized, 
and stained for IFN-g. Cells were examined by flow cytometry, and IFN-g expression was 
measured as an activation index. For in vivo experiments, spleens were harvested from 
mice at different time points after vaccination. Spleens were processed into single cells, 
stained for CD8 and IFN-g, and interrogated by flow cytometry as described above.  
In vivo vaccination. For early lymphocyte activation experiments, OT-I transgenic 
mice received 20 µg of Kb(Ova) or Kb(Ova)/ANXA5 via intravenous injection. 
Splenocytes were harvested the following day for analysis. For vaccination experiments, 
C57BL/6 or 232-4 transgenic mice received protein (20 µg) via subcutaneous injection 
twice at a 7-day interval. After two weeks, splenocytes were removed for analysis. For 
30 
	
lymphocyte proliferation experiments, C57BL/6 mice were adoptively transferred CFSE-
labeled OT-I cells (106 per animal) by intravenous injection. After one day, mice received 
protein (ranging from 0.1-10 µg) via intravenous injection. On day five, PBMCs were 
collected and assessed for CFSE dilution by flow cytometry. 
Altered peptide ligands (APLs). Single amino acid substitutions in the SIINFEKL 
(N4) peptide of Kb(Ova)/ANXA5 were generated by recombinant DNA technology to 
mimic low affinity pMHC-TCR interactions. Constructs were verified by DNA 
sequencing. The altered encoded peptide epitopes were: SIYNFEKL (Y3), SIIQFEKL 
(Q4), and SIITFEKL (T4). pMHC/ANXA5 containing APLs were incubated with resting 
OT-I cells for lymphocyte activation experiments as described above. 
Synthesis of ANXA5 mutants. Amino acid substitutions were introduced in the 
calcium-binding domain of ANXA5 in pMHC/ANXA5 to disrupt PS binding: D144N and 
E228Q (mt136) or D144N, E228Q, and D303N (mt137) by recombinant DNA technology. 
To abolish ANXA5 aggregation, an altered ANXA5 molecule bearing five substitutions in 
the self-assembly domain was generated: R16E, R23E, K27E, K56E, K191E (mt5). 
Constructs were confirmed by DNA sequencing, and structural or functional alterations in 
the encoded protein were verified by SDS-PAGE as well as the liposome-based assays 
described above. 
Single-molecule epifluorescence microscopy. Kb(Ova)/ANXA5 or Kb(Ova) 
protein was mixed with PE-labeled a-his tag antibody for 30 min and then added to resting 
OT-I cells pre-seeded at 300 cells/mm2. Cells were incubated at 37°C for 5 hr, washed, and 




Statistical analysis. All data in this study are presented as mean ± standard 
deviation (SD) and are representative of at least three independent experiments performed. 
Individual data points from flow cytometry results were evaluated by Student’s t-test. P-






Figure II-1. Schematic diagram of the pMHC/ANXA5 system concept. 
(a) Phosphatidylserine (PS) exposure upon cognate pMHC-TCR interactions is exploited 
to tether pMHC to the membrane via ANXA5, stabilizing pMHC-TCR binding and 
prompting TCR crosslinking. In this system, weak and transient pMHC-TCR encounters 
are converted into strong, repeated binding events by ANXA5, which induces further PS 
exposure in a positive feedback loop. Self-assembly of ANXA5 on the membrane 
facilitates TCR crosslinking and robust lymphocyte activation. (b) Model of the soluble 
pMHC/ANXA5 protein, composed of antigen epitope at the N-terminus linked to b2 




Figure II-2. Phosphatidylserine (PS) exposure on cognate T cells upon antigen 
stimulation. 
(a) PS exposure on OT-I cells pulsed with SIINFEKL-loaded feeder cells for 12 hr. Cells 
were stained with FITC-labeled ANXA5 or buffer control and examined by flow 
cytometry. Live, activated T cells were gated by FSC/SSC profile (dot plot, top), and 
fluorescence was measured (histograms, bottom). (b) Kinetics of PS exposure on resting 
OT-I cells pulsed with peptide. (c) PS exposure on naïve splenocytes incubated with plate-
coated a-CD3 antibody for 12 hr. Splenocytes were stained with fluorophore-labeled CD8, 
CD69, and ANXA5 antibodies. CD8+ T cells were gated by FSC/SSC profile and CD8 
expression, and the distribution of CD69+ and/or ANXA5+ cells is shown in the dot plots. 
(d) Quantification of PS exposure on naïve splenocytes with or without a-CD3 stimulation. 
Activation of splenocytes was measured by CD69 expression. Data are representative of 




Figure II-3. Lymphocyte activation by pMHC/ANXA5. 
(a) Resting OT-I cells were incubated for 12 hr with Kb(Ova) or Kb(Ova)/ANXA5 at 2.5 
µg/ml in the presence of brefeldin A. Activation of CD8+ T cells was determined by flow 
cytometry analysis of IFN-γ expression. (b) Bar graph quantification of lymphocyte 
activation frequency (n=3). (c) Resting OT-I cells or (d) splenic T cells harvested freshly 
from OT-I transgenic mice were incubated for 12 hr with Kb(Ova) or Kb(Ova)/ANXA5 at 
various molar concentrations. Activation of T cells was determined by flow cytometry 
analysis of IFN-γ expression. Data are representative of results from at least three 




Figure II-3 (continued). Lymphocyte activation by pMHC/ANXA5. (e) Proliferation of T 
cells by pMHC/ANXA5. Resting OT-I cells were labeled with CFSE and incubated with 
ANXA5, Kb(Ova), or Kb(Ova)/ANXA5. Proliferation was measured after three days 
based on CFSE dilution. Histograms (left) display CFSE intensity and bar graph (right) 
depicts the frequency of T cells that underwent proliferation (n=3). Data are representative 





Figure II-4. In vivo activation of antigen-specific T cells by pMHC/ANXA5. 
(a) Early costimulation-independent lymphocyte activation by pMHC/ANXA5. OT-I 
transgenic mice were administered Kb(Ova) or Kb(Ova)/ANXA5, and the percentage of 
CD69+ CD8+ T cells was measured after one day by flow cytometry. Left: representative 
dot plots, right: bar graph quantification (n=3 mice per group). (b) Amplification of rare 
antigen-specific lymphocyte precursors by pMHC/ANXA5. C57BL/6 mice were 
administered Kb(Ova) or Kb(Ova)/ANXA5, and activation of Ova-specific CD8+ T cells 
was assessed after two weeks based on IFN-g expression. Left: experiment timeline, right: 
bar graph depicting frequency of lymphocyte precursors post-vaccination (n=5 mice per 





Figure II-4 (continued). In vivo activation of antigen-specific T cells by pMHC/ANXA5. (c) 
Proliferation of systemic cognate T cells by pMHC/ANXA5. CFSE-labeled OT-I cells 
were adoptively transferred into C57BL/6 mice (n=5 mice per group), followed by 
Kb(Ova) or Kb(Ova)/ANXA5 infusion. Lymphocyte proliferation was monitored by CFSE 
dilution. Left: experiment timeline, right: proliferation index. EC50, minimum injection 
dose needed to elicit 50% proliferation. (d) Reversal of immune tolerance to self-antigen 
by pMHC/ANXA5. Transgenic 232-4 mice with ectopic expression of Ova antigen in the 
intestine were administered with either Kb(Ova) or Kb(Ova)/ANXA5 by subcutaneous 
injection. The frequency of IFN-γ+ CD8+ T cells was determined by flow cytometry. Left: 




Figure II-5. Reversal of low-affinity pMHC-TCR interactions by ANXA5 fusion to pMHC. 
 (a) Phosphatidylserine (PS) exposure on cognate T cells in response to weak antigen 
stimuli. OT-I cells were incubated with monomeric Kb(Ova) protein. Cells were stained 
after one day with FITC-labeled ANXA5, and the frequency of PS+ T cells was measured 
one day later by flow cytometry. Bar graph depicts frequency of PS+ cells (n=3). (b, c) 
Lymphocyte activation by pMHC/ANXA5 in the context of low affinity pMHC-TCR 
interactions. ANXA5-linked altered peptide ligands carrying indicated single amino acid 
substitutions in the SIINFEKL epitope were incubated with OT-I cells. (b) The frequency 
of IFN-g+ T cells was quantified (n=3). (c) Bar graph depicting the ratio of the amount of 
pMHC/ANXA5 protein, with wildtype or mutant Ova epitopes, needed to prime 50% of T 
cells (EC50). Data are representative of results from at least three independent experiments 




Figure II-6. Mechanisms underlying lymphocyte activation by pMHC/ANXA5. 
(a) Calcium dependence of lymphocyte activation by pMHC/ANXA5. T cells were 
incubated for 12 hr with Kb(Ova) or Kb(Ova)/ANXA5 in medium containing different 
calcium concentrations. Lymphocyte activation was determined based on IFN-g 
expression. EC50, minimum protein amount needed to reach 50% activation. (b, c) Effect 
of structural ANXA5 mutations on lymphocyte activation by pMHC/ANXA5. 
Kb(Ova)/ANXA5 carrying mutations that disrupt either (b) the calcium-binding domain 
domain (D144N, E228Q (mt136) or D144N, E228Q, D303N (mt137)) or (c) the self-
assembly domain (R16E, R23E, K27E, K56E, K191E (mt5)) were for 12 hr with OT-I 
cells. Lymphocyte activation was assessed by IFN-g expression. Data are representative of 




Figure II-7. Antigen membrane tethering, TCR crosslinking, and TCR downregulation 
mediated by pMHC/ANXA5. 
His tag+ Kb(Ova) or Kb(Ova)/ANXA5 was pre-mixed with PE-labeled α-his tag antibody 
and then incubated with low-density (~300 cells/mm2 density) resting OT-I cells at 37°C 
for 5 hr. Cells were stained for CD8 and TCR (Vα2), and examined for fluorescence by 
flow cytometry. (a) Left: representative dot plots. Right: the percentage of T cells classified 
into indicated categories of TCR surface density and pMHC binding was quantified. (b) 
Cells were visualized by single-molecule epifluorescence microscopy. Representative 





Supplementary Figure II-1. Validation of pMHC/ANXA5. 
Ni-NTA liposomes were coated with Kb(Ova) or Kb(Ova)/ANXA5 protein (both bearing 
his tags) and then stained with a-H-2Kb-SIINFEKL antibody to verify peptide display. (a) 
Histogram and (b) bar graph depicting relative pMHC density on liposomes (n=3). Data 




Supplementary Figure II-2. Assay of pMHC/ANXA5 binding to phosphatidylserine (PS). 
PS-containing liposomes were treated with Kb(Ova) or Kb(Ova)/ANXA5 and stained with 
a-H-2Kb-SIINFEKL antibody. (a) Histogram and (b) bar graph depicting relative pMHC 




Supplementary Figure II-3. Viability of T cells treated with pMHC/ANXA5. 
OT-I cells were incubated with indicated proteins. After three days, lymphocyte viability 
was assessed by 7-aminoactinomycin D (7-AAD) staining. (a) Histogram of 7-AAD 
intensity and (b) bar graph depicting the percentage of live cells in each group (n=3). Data 




Supplementary Figure II-4. Comparison of lymphocyte activation by Kb(Ova)/ANXA5 to 
dimeric Kb(Ova)/Fc or tetrameric Kb(Ova). 
Resting OT-I cells were incubated with indicated concentrations of Kb(Ova), Kb(Ova)/Fc, 
or tetrameric Kb(Ova). IFN-g expression was measured as an index of lymphocyte 
activation. (a) Line graph depicting the percentage of IFN-g+ T cells at different Kb(Ova), 
Kb(Ova)/ANXA5, or Kb(Ova)/Fc concentrations. (b) Table of EC50 values, defined as the 
minimum protein amount required for 50% activation. (c) Bar graph depicting the 
percentage of IFN-g+ T cells at 2.5 µg/ml Kb(Ova)/ANXA5 or tetrameric Kb(Ova) (n=3). 




Supplementary Figure II-5. Proliferation of systemic cognate T cells by pMHC/ANXA5. 
CFSE-labeled OT-I cells were transferred into C57BL/6 mice, followed by Kb(Ova) or 
Kb(Ova)/ANXA5 infusion at various doses. Lymphocyte proliferation was monitored by 




Supplementary Figure II-6. Requirement for pMHC-ANXA5 fusion for lymphocyte 
activation by the dynamic anchor. 
Resting OT-I cells were incubated for 12 hr with ANXA5, Kb(Ova), combined ANXA5 
and Kb(Ova), or Kb(Ova)/ANXA5 fusion protein. Lymphocyte activation was measured 





Supplementary Figure II-7. Lymphocyte activation by pMHC/ANXA5 in the presence of 
excess ANXA5. 
Resting OT-I cells were incubated for 12 hr with a mixture of Kb(Ova)/ANXA5 and 
ANXA5 at various molar ratios (from 1:1 to 1:00). Lymphocyte activation was measured 
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III. Chapter 3. Single-molecule profiling of circulating mutant 
tumor proteins 
 
Quantitative and structural analysis of circulating mutant tumor proteins may 
provide insight into disease in cancer patients. However, these proteins are rare in the 
circulation and therefore inaccessible to existing methods. We developed an imaging 
technology based on total internal reflection fluorescence microscopy in a 
microfluidic device to identify circulating mutant tumor proteins at single-molecule 
resolution and characterize their structural composition. As proof-of-principle, we 
focused on the p53 transcription factor, which is almost universally altered in human 
high-grade serous ovarian cancer1. Our technology identified the presence of mutant 
p53 in plasma from ovarian cancer patients and revealed that it aggregates into 
complexes of diverse size. Furthermore, single-molecule imaging discovered that 
patients who lacked circulating mutant p53 produced abundant anti-p53 
autoantibodies, suggesting that host immune responses clear mutant tumor proteins 
from the blood. Structural analysis of circulating tumor proteins and their cognate 
autoantibodies introduces new possibilities for minimally invasive disease profiling. 
Blood-based cancer detection, diagnosis, and monitoring currently centers around 
measurement of tumor biomarker levels2. Emergent techniques, such as digital ELISA3, 
DNA biobarcoding4-6, proximity ligation7, 8, or immuno-PCR9-11, have substantially 
lowered the detection limit of biomarker assays, often pushing sensitivity into the attomolar 
(aM) range12. However, strictly quantitative conventional biomarker measurement suffers 
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from limited specificity due to potential basal release of these proteins from non-
transformed cells into the blood2. Also, existing methods do not yield information about 
structural features of tumor-derived proteins. Because mutant oncoproteins or tumor 
suppressor proteins are exclusive to tumor cells and frequently possess unique structural 
characteristics, we reasoned that the analysis of these characteristics would improve the 
specificity of disease detection, as well as shed light on biochemical features of a tumor 
that may be amenable to therapy. 
To characterize structural features of circulating mutant tumor proteins, we 
developed an imaging technology based on single-molecule total internal reflection 
fluorescence microscopy (TIRFM). By interrogating individual proteins in space, TIRFM 
provides structural information about proteins that cannot be attained via standard ultra-
sensitive assays. For instance, Ha and coworkers used single-molecule TIRFM to dissect 
the composition of various complexes of cytosolic, membrane, and organelle-associated 
proteins13. In addition, Lee et al. implemented this technique to investigate the kinetics of 
Ras signaling in vitro14. However, TIRFM-based methods have thus far not reached a 
detection limit below the pM (10-12 M) range, restricting their utility in the clinical setting13, 
15. Indeed, TIRFM has not been previously applied to study proteins in clinical samples 
such as human blood. Here we report a TIRFM platform—which we call SiMSI (for 
Single-Molecule Structural Imaging)—that provides structural insight into proteins with 
single-molecule resolution at a sub-fM (<10-15 M) concentration range, >103-fold below 
current TIRFM-based techniques. We applied SiMSI to profile rare mutant tumor proteins 
and their cognate autoantibodies in blood from cancer patients. 
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Our technology capitalizes on the principle of single-molecule pulldown16 on a 
borosilicate surface passivated with a high-density mixture of 5 kD polyethylene glycol 
(PEG) and a biotinylated PEG functional group18, which serves as an attachment site for 
antibodies conjugated via a NeutrAvidin linker. To concentrate target protein in a 1.8 mm2 
region, we covalently assembled the surface to a microfluidic chamber (200 µm width ´ 
200 µm height) patterned with a staggered herringbone micromixer16 (Figure III-1a). We 
continuously passed samples at 500 µl/min in the chip to capture target protein with >100-
fold greater efficiency over standard incubation (Supplementary Figure III-1a, b). We 
probed for target protein with fluorophore-labeled antibodies and applied a stringent wash 
regimen with 104-fold chip volume to confine background to <10 non-specific binding 
events per imaging area. We performed single-molecule TIRFM on the chip over a time 
stream of 500 frames with 50 ms exposure time. We set each imaging area at 625 µm2 for 
a total of ~3,000 imaging regions per chip. For data analysis, we applied a dynamic 
thresholding algorithm to digitally count the number of protein copies per imaging area 
and to localize protein complexes to 20-nm resolution (Figure III-1a and Supplementary 
Figure III-2a, b). We deduced the structural composition of complexes by inspecting 
fluorescence data with integrated Gaussian multiple emitter fitting analysis (Figure III-
1a). 
We first evaluated SiMSI using GFP as a reporter protein. We detected down to 
<500 aM (10-18 M) GFP (Figure III-1b), which corresponds to >50% capture efficiency. 
In general, this system attains >10% capture efficiency with antibodies of KD~10-9 M 
affinity. Within the aM to pM range, molecule counts scaled linearly with target 
concentration (R2=0.9987) (Figure III-1b). For imaging convenience, we maintained a 
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capture area of 1.8 mm2 in this study, although we have observed that shrinking this area 
further augments sensitivity. At this chip size, our technology displays a sensitivity 104-
fold greater than ELISA (Figure III-1b) and >103-fold superior to that previously achieved 
by single-molecule TIRFM13, 15. Since a fraction of GFP naturally dimerizes17, 18, to 
validate SiMSI for structural analysis we examined the fluorescence distribution of this 
protein in its native state. As expected, GFP singlets emitted half the median intensity of 
doublets (Supplementary Figure III-3a, b). Based on these intensity values, we 
calculated the number of protein copies per imaging spot. Even at sub-fM concentrations, 
SiMSI could profile the size distribution of native protein with high resolution (Figure III-
1c, d). This type of structural analysis has not been previously realized for such low 
amounts of target protein. 
To illustrate the application of SiMSI to circulating tumor molecule structural 
analysis, we conducted proof-of-principle experiments in preclinical models to profile rare 
cytoplasmic proteins shed from tumor cells into the blood. Notably, almost all existing 
cancer biomarker assays measure membrane-associated or secreted proteins19, and 
circulating cytoplasmic tumor-derived proteins (including mutant proteins) have not been 
rigorously explored. In mice with tumor cells carrying a cytoplasmic GFP reporter, SiMSI 
(but not ELISA) readily detected circulating GFP (>100-fold above background) within 
days after tumor challenge (Figure III-1e). The high sensitivity of this technology 
permitted us to study the kinetics and mechanism by which cytoplasmic tumor proteins 
enter the blood. We induced spontaneous tumor formation in mice by in vivo oncogene 
delivery20, with cytoplasmic GFP and luciferase acting as tracers of tumor progression 
(Supplementary Figure III-4). Intriguingly, circulating GFP release was only observed 
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with concomitant oncogene (Ras, Akt) delivery (Supplementary Figure III-5, 6), 
implying that transformation instigates the release of cytoplasmic proteins from cells. 
Single-molecule imaging revealed that circulating cytoplasmic tumor proteins but not 
DNA emerge around one month after oncogenesis (before a tumor was visible on 
luminescence imaging) (Figure III-1f and Supplementary Figure III-7, 8), and 
accumulated with progressive tumor burden (Figure III-1g). By single-molecule structural 
analysis, we found that circulating GFP load correlated with formation of serum complexes 
(Figure III-1h), suggesting that a high density of cytoplasmic tumor proteins promotes 
their aggregation in the blood. Collectively, these results establish that SiMSI is able to 
identify and profile structural features of rare cytoplasmic proteins shed from tumor cells 
into the blood. 
Since transformed cells release their contents into the blood via an oncogene-driven 
process, we reasoned that mutant tumor proteins, such as mutant Ras, may appear in the 
blood as well. We detected circulating Ras at ~100-fold higher levels in serum from mice 
bearing tumor cells with mutant compared to wildtype Ras independent of tumor growth 
rates (Figure III-2a), suggesting that mutant Ras facilitates its own export into the blood. 
As Ras has been shown to polymerize on the plasma membrane into transient 
nanoclusters21, we observed these nanoclusters by SiMSI (Figure III-2b, c). In tumor-
bearing mice, 1-4% of circulating mutant Ras (but not wildtype Ras) formed nanoclusters 
(Figure III-2d, e). Our data signify that circulating mutant Ras oncoproteins present an 
attractive target for cancer detection because they selectively enter the blood and are 
specific for transformed cells. To this end, we developed a preliminary SiMSI system that 
preferentially recognizes RasG12V and RasG12D (Figure III-2f), the variants that occur most 
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frequently in human cancer22. We are currently optimizing this system for clinical 
translation. 
To build on the concept of circulating mutant protein detection, we next focused on 
the transcription factor p53. 96% of high-grade serous ovarian cancer cases carry mutant 
p531. Moreover, while the proteasome rapidly degrades wildtype p53, mutant p53 evades 
the proteasome and accumulates within tumor cells23, 24. By SiMSI we detected <10 fM 
mutant p53 (R2=0.9552), 104-fold below the ELISA limit (R2=0.9939) (Figure III-2g). 
Furthermore, SiMSI detected p53 from cancer cells carrying multiple different p53 amino 
acid substitutions, but not from cells carrying wildtype p53 (Figure III-2h), indicating that 
this system is specific for mutant p53, likely due to stabilization of the mutant protein. 
We applied SiMSI to characterize structural aspects of mutant p53. Conformational 
alterations in mutant p53 cause this transcription factor to precipitate into large complexes, 
a property that fosters oncogenesis25, 26. Thus, we verified this system in cells transfected 
with GFP-linked wildtype p53 or mutant p53 variants that either aggregate into large 
complexes (p53R175H) or fail to aggregate (p53L344P)25, 26 (Figure III-2i-k and 
Supplementary Figure III-9, 10). In cells with p53R175H (but not p53L344P or wildtype 
p53), we observed distinct imaging peaks corresponding to p53 tetramer, octamer, and 
large (>10-mer) complexes (Figure III-2i-k). We applied this system to investigate mutant 
p53 shed from cancer cells into the surrounding milieu. We detected non-vesicular mutant 
p53 release from as few as 103 human ovarian cancer cells (OVCAR3; p53R248Q) within 24 
hr (Figure III-2l, Supplementary Figure III-11). To explore the structural features of 
mutant p53 before and after release from human cancer cells, we mapped the size 
distribution of mutant p53 in the nucleus, cytoplasm, and supernatant (Figure III-2m, 
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Supplementary Figure III-12a, b). As mutant p53 transitioned from nucleus to 
supernatant, complexes became remarkably diverse in size and on average ~30% smaller 
(Figure III-2m), implying that mutant p53 complexes partly dissociate during release. We 
implemented SiMSI to identify circulating mutant p53 early in tumor progression and to 
monitor disease dissemination in preclinical spontaneous tumor models (Figure III-2n and 
Supplementary Figure III-13-16). Together, these data highlight the utility of SiMSI in 
characterizing the structural composition of rare circulating mutant p53 complexes. 
We therefore applied this technology to profile circulating mutant p53 in cancer 
patients. We verified that this system maintains a sensitivity of ~10 fM p53 in human 
plasma (R2=0.9017) with negligible background across multiple subjects (Figure III-3a 
and Supplementary Figure III-17, 18). Structural analysis also indicated that mutant p53 
complexes remain stable in human plasma (Figure III-3b-d). To profile structural 
properties of endogenous circulating mutant p53, we ascertained the fluorescence pattern 
of anti-p53 probe monoclonal antibodies, which split into distinct populations due to 
variation in dye labeling ratios (R2=0.9874) (Figure III-3e, f). We used this data to project 
the number of proteins within mutant or wildtype p53 complexes (Figure III-3g). 
By quantifying circulating p53 complexes, we detected circulating mutant p53 in 
~50% of high-grade serous ovarian cancer patients (Figure III-3h); patients were 
confirmed to have tumor tissue p53 by immunohistochemistry. Moreover, healthy control 
subjects lacked circulating mutant p53 (Figure III-3h). We examined structural features 
of circulating mutant p53 in two patients by SiMSI and found that it polymerized into 
complexes of diverse size, with an average of 17.3±8.1 and 24.2±12.0 p53 copies/aggregate 
(Figure III-3i, j and Supplementary Figure III-20). The mutant p53 profile in these 
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patients differed conspicuously from background plasma signal in healthy subjects (Figure 
III-3i, j and Supplementary Figure III-20). Our results insinuate that these patients may 
harbor mutant p53 with conformational anomalies and underscore the power of single-
molecule imaging to trace these structural alterations in a minimally invasive manner. 
We reasoned that in patients who lacked circulating mutant p53, this protein may 
be depleted from the blood by host autoantibodies27. Since ELISA-based methods 
potentially miss autoantibodies in many patients, we developed a single-molecule assay for 
circulating anti-p53 autoantibodies, which performed with >103-fold superior sensitivity 
over ELISA (Figure III-3k). In a subset of our initial cohort of ovarian cancer patients, 
anti-p53 autoantibodies were markedly amplified as assessed by SiMSI (Figure III-3l and 
Supplementary Figure III-21). Remarkably, most patients with abundant p53 
autoantibodies lacked circulating mutant p53, suggesting that host immune responses clear 
mutant tumor antigens from the blood. Overall, we detected circulating mutant p53 or 
amplified anti-p53 autoantibodies in ~80% (11 of 14) of ovarian cancer patients and in 0% 
(0 of 11) of control subjects (Figure III-3m). Thus, we conclude that the presence of 
circulating mutant proteins and their cognate autoantibodies are complementary, though 
not mutually exclusive, events in human cancer. These results warrant large-cohort studies 
employing single-molecule imaging to simultaneously characterize circulating mutant 
tumor proteins and their autoantibodies. 
Altogether, we have shown that rare circulating mutant tumor proteins and their 
autoantibodies can be profiled by single-molecule imaging technology. We believe the 
structural and functional information to be garnered from this technology holds value, as it 
may shed light on the pathologic processes unfolding within the tumor of individual cancer 
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patients and point to effective management strategies. Thus, single-molecule profiling of 
mutant proteins and antibodies may be useful for cancer detection, diagnosis, and 
monitoring. Finally, this technology may also be applied to investigate other cancer-
associated proteins that form complexes or different permutations of proteins within these 
complexes. For instance, Rodina et al. recently reported the concept of an ‘epichaperome’ 
of cancer, in which oncoproteins such as Myc rewire chaperone proteins, causing them to 
assemble into large complexes that promote cancer progression28. Intriguingly, emergence 
of the epichaperome occurs in a majority of cancer cases, and pharmacologic inhibition of 
the epichaperome impairs tumor survival28. Therefore, the structural analysis of these 
chaperone complexes, or other key tumor signaling machinery, in the blood might uncover 
new avenues for clinical intervention. 
 
Methods 
Materials. Polydimethylsiloxane (PDMS) elastomer for synthesis of SiMSI chips 
was purchased from Dow Corning. 22´22 mm borosilicate cover glass for the capture 
surface was from Fisher Scientific. Surface passivation relied on the following reagents: 
aminosilane (United Chemical Technologies), Alconox (Alconox, Inc.), methanol (Fisher 
Scientific), acetic acid (Sigma-Aldrich), sodium bicarbonate (Sigma-Aldrich), biotin-
mPEG-succinimidyl valerate (biotin-mPEG-SVA) (Laysan Bio), and mPEG-SVA (Laysan 
Bio). Multiple anti-p53 antibodies were used, including: E47, Y5 (Abcam); 7F5 (Cell 
Signaling Technology); BAF1355 (R&D Systems); pAb240, DO-1, FL-393 (Santa Cruz 
Biotechnology); DO-7 (Thermo Scientific). For most applications in this study, BAF1355 
was utilized for capture and E47 (C-terminus) or Y5 (N-terminus) for detection. Clones of 
62 
	
anti-Ras antibodies used were: RAS10 (pan-Ras-specific, Millipore); D2H12 (G12V-
specific), or D8H7 (G12D-specific) (Cell Signaling Technology). Fluorophore-labeled 
secondary antibodies were purchased from Thermo Scientific. Anti-GFP (clone RQ2, 
MBL) was used for GFP pulldown experiments. BSA was from New England BioLabs. 
ELISA was performed with GFP ELISA Kit (Cell Biolabs) or p53 SimpleStep ELISA Kit 
(Abcam) according to the manufacturer’s instructions. 
Antibody conjugation. Antibodies were labeled with biotin or organic 
fluorophores via NHS-reactive ester. For biotin conjugation, antibodies were incubated 
with 50-fold molar excess of NHS-LC-biotin (Thermo Scientific) for 30-60 min and then 
isolated on 7 kD gel filtration columns (Thermo Scientific). For dye conjugation, 
antibodies were pre-captured on protein G magnetic beads and incubated with 10-fold 
molar excess of Alexa Fluor-NHS dye (Thermo Scientific) for 30-60 min. Free dye was 
washed out, and antibodies were further purified on 7 kD gel filtration columns (Thermo 
Scientific). Degree of labeling and concentration was measured by spectrophotometry. 
Cells. TC-1 tumor cells were previously generated in our laboratory and have been 
reported29. Cells carrying mutant p53 (CFPAC-1 (C242R), OVCAR3 (R248Q), and TOV-
112D (R175H)), cells with wildtype p53 (MCF-7, MCF-10), HEK 293 cells, and BHK21 
cells were obtained from ATCC. Cells were cultured in RPMI-1640 medium or DMEM 
with 10% FBS and maintained under 5% CO2 atmosphere. Lysate was prepared with 
commercial buffer containing 10% Triton X-100 in Tris-HCl (Abcam). Harvested 
supernatant was centrifuged at 10,000´g for 10 min and then passed through 0.22 µm filters 
to remove debris. 
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Mice. 6- to 8-week old female C57BL/6 and athymic nude (Foxn1-/-) mice were 
obtained from the National Cancer Institute. All animal procedures complied with 
protocols approved by the Johns Hopkins Institutional Animal Care and Use Committee 
and with recommendations for the proper use and care of laboratory mice. 
Capture surface passivation. A borosilicate glass substrate of 130-170 µm 
thickness and 22´22 mm area was chosen for the capture surface. The substrate was first 
cleaned with ultrapure Milli-Q water (Millipore) in an ultrasonic bath for 10 min, dried 
under a stream of filtered air, exposed to high power atmospheric plasma (Plasma Etch, 
PE25-JW) for 5 min for surface activation, and then immediately dipped in methanol 
containing 1% N-(2-aminoethyl)-3-aminopropyltrimethoxysilane and 5% glacial acetic 
acid. The substrate was washed thoroughly with methanol and ultrapure water, dried under 
a stream of filtered air, and conjugated with biotin-mPEG-SVA (0.3 mg) in 10 mM sodium 
bicarbonate (pH 8.5) for 12 hr. The glass surface was then conjugated with a mixture of 
biotin-mPEG-SVA (0.3 mg) and PEG-mSVA (16 mg) (1:50 mass ratio) for 12 hr. After 
passivation, the substrate was washed with ultrapure water and dried as described above. 
The substrate was transferred to a clean container, vacuumed, flushed with pure nitrogen, 
sealed, and stored at -20°C. 
Fabrication of SiMSI chip enclosure. The SiMSI chip was synthesized by 
photolithography. Briefly, a silicon wafer was rinsed with acetone and isopropanol, and 
then dehydrated at 200°C. The wafer was exposed to high power oxygen plasma (100 W 
for 3 min at 300-500 mTorr oxygen pressure) to promote photoresist adhesion. SU-8 
photoresist was spin-coated onto the wafer to 100 µm thickness. The wafer was then soft-
baked (65°C/95°C) and exposed to UV light in a mask aligner loaded with a mask printed 
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at 32,512 DPI resolution. The wafer was then hard-baked (65°C/95°C). The first layer of 
the SiMSI chip consists of the main channel with side boxes while the second layer consists 
of the arrays of staggered herringbone grooves. After all layers of photoresist were 
deposited, the wafer was developed under ultrasonic agitation to yield a master template 
for synthesis of the silicone elastomer chip enclosure. To produce this enclosure, PDMS 
elastomer was mixed with curing agent in a 10:1 ratio (by weight), poured onto the 
patterned wafer, degassed, and incubated at 80°C overnight. The PDMS was then removed 
from the master, cut into individual devices, and bored with inlet/outlet tubing holes (750 
µm diameter). The devices were washed in an ultrasonic bath with isopropanol for 20 min 
and then with ultrapure water for 5 min. Devices were dried under a stream of filtered air. 
Assembly of SiMSI chip. Prior to bonding, the coated glass substrate was attached 
to an alignment guide patterned with an imprint matching the shape and size of the flow 
channel. An elastomer cover fabricated with µm precision to the exact dimensions of the 
flow channel was then placed on top of the glass surface at the position of the channel 
imprint on the alignment guide. This cover permits the glass surface to be activated for 
bonding via oxygen plasma while preserving the high-density PEG/biotin-PEG passivation 
in the flow channel. Absence of this cover would cause the PEG/biotin-PEG layer to be 
destroyed by oxygen plasma bombardment. The coated glass surface (with elastomer 
cover) and PDMS devices were placed inside a plasma etcher and treated with oxygen 
plasma for 30 sec at 40 W RF power under 300-400 mTorr oxygen atmosphere. The 
elastomer cover was removed, and PDMS devices were then sealed to the coated glass 
substrate under a stereomicroscope with the alignment guide as a reference for the channel 
position. Chips were incubated at 80°C for 3 min to drive the bonding to completion. 
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Capture reagent conjugation to the SiMSI chip. Reagent introduction, removal, 
and wash steps were performed under automated flow actuated by a multi-channel 
peristaltic pump. SiMSI chips were connected to connected to inlet and outlet 
polytetrafluoroethylene tubing, and equilibrated with 10 mM Tris-HCl pH 8.0, 50 mM 
NaCl, 0.05% Tween-20 (T50) buffer. Chips were incubated with NeutrAvidin (20 µl; 0.1 
mg/ml) in T50 buffer for 10 min at 50 µl/min flow rate. Chips were then washed with T50 
buffer (1 ml) at 500 µl/min and incubated for 30 min with capture antibodies (2 µl; 0.1-1 
mg/ml) in T50 buffer with 0.1 mg/ml BSA (T50-BSA). Chips were then washed with T50-
BSA (1 ml) at 500 µl/min. 
Sample circulation. Continuous circulation was actuated by a multi-channel 
infusion/withdrawal pump (bidirectional flow) connected to SiMSI chips via 26-gauge 1-
cc syringes. Chips were connected at the other tubing port to the sample prepared in T50-
BSA buffer. The presence of Tween-20 in the sample buffer is critical for preventing 
absorption of target proteins to the hydrophobic PDMS walls. For circulation, the pump 
was programmed to carry out repeated infusion/withdrawal cycles at 500 µl/min for 2-4 hr. 
After circulation, chips were washed with T50-BSA buffer (1 ml) at 500 µl/min, incubated 
with fluorophore-labeled detection antibodies for 30 min, and then washed again. 
Single-molecule TIRF microscopy. An objective-based TIRF setup was 
employed with a 60× objective of high numerical aperature (>1.45). The incident laser 
angle was adjusted to full TIRF mode with a prism. Flow channels in the SiMSI chip were 
identified by patterned side boxes, which delineate the boundaries of the channel. An 
imaging region of 150×150 pixels, which translates to a physical area of 625 µm2, was then 
set. The size of this region corresponds to the approximate size of the laser spot. An 
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EMCCD camera (Andor) was programmed to capture a time stream of 500 consecutive 
frames with 50 ms exposure time under continuous laser excitation of 10-20 mW. After 
imaging each region, the stage was displaced 50 µm down the length of the channel, and 
imaging was performed again as above. This process was repeated until at least 10 
micrographs were recorded per sample. 
Digital molecule quantification. Single-molecule TIRF data was analyzed with 
the ThunderSTORM program. In the quantification algorithm, a test was first applied to 
every pixel p in an imaging area of 150×150 pixels. The criteria for this test were that: (1) 
p has an intensity value that exceeds a defined threshold value, and (2) the intensity value 
of p exceeds the intensity value of all its four xy neighboring pixels. If p satisfies the criteria 
above, then it was chosen for further data processing; otherwise, p was excluded. 
The exact positions of fluorophore-labeled target molecules within each pixel p that 
passed the above test were then determined by analysis of its point spread function. The 
number of target molecules with unique positions was counted; molecules separated in the 
imaging field by a distance below a certain value (for example 1-50 nm) were considered 
a single entity and hence only counted once. Molecules that occupied identical positions 
over multiple imaging frames were merged to compensate for blinking or slow 
photobleaching. Thus, the final readout was the total number of unique fluorophore-labeled 
target molecules in each imaging field (displayed as ‘counts per field’). 
The cutoff threshold was set individually for each target protein. To determine the 
threshold for a particular target molecule, a SiMSI calibration test similar to that described 
in Supplementary Figure III-2a, b was performed with two groups: (1) a defined 
concentration of the target protein in buffer (positive control), and (2) buffer only without 
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the target protein (negative control). The algorithm described above was applied to both 
groups, and the number of counts per field in each control was calculated over threshold 
intensities ranging from 103 to 1.6´104. The number of counts per field in the positive 
control was divided by that in the negative control at each threshold value to compute the 
signal-to-noise ratio for that threshold value. The threshold that yielded the highest signal-
to-noise ratio was chosen for SiMSI analysis of the particular target protein. 
Single-molecule structural analysis. The first frame of 500 in each imaging region 
was isolated and stacked into a micrograph series. A wavelet filter was applied, and 
fluorescent spots that scored >1.3 standard deviations above the mean intensity in an eight-
molecule neighborhood were selected for analysis. Individual molecule spatial coordinates 
were determined by integrated Gaussian multiple-emitter fitting. The σ values of each 
molecule were interrogated, and spots with σ within the 25-75 percentile were selected for 
further processing. Fluorescence intensity values were examined to characterize the size 
distribution of protein complexes, and these values were converted to subunits per 
aggregate based on single probe intensity profiles. We created a program in MATLAB to 
automatically compute the average aggregate frequency based on pre-defined size criteria. 
Transplanted tumor challenge. C57BL/6 or athymic mice (n=5 per group) were 
inoculated with TC-1 tumor cells (105 per animal) by subcutaneous injection in the flank 
or oropharyngeal injection into the buccal mucosa. At different time points after tumor 
challenge, whole blood was collected from the tail vein and processed into serum for 




Spontaneous tumor induction. Athymic mice (n=5 per group) were administered 
plasmid DNA (10 µg each, 30 µl total volume) encoding RasG12V, SB13 transposase, 
luciferase, and either anti-p53 shRNA or mutant human p53R175H by injection into the 
buccal mucosa. Immediately afterwards, mice received electroporation (eight pulses of 72 
V, 50 ms duration, and 200 ms interval) at the injection site with an ECM830 device (BTX). 
Tumor burden was monitored over time by whole body luminescence imaging with an 
IVIS Spectrum device (PerkinElmer). At different time points after tumor challenge, whole 
blood was collected from the tail vein and processed into serum for SiMSI. 
Digital autoantibody detection. Recombinant human p53 protein was biotinylated 
at the C-terminus in a site-specific manner using the BirA biotin protein ligase30. The 
purified biotinylated protein was conjugated to SiMSI chips. Plasma samples were diluted 
from 103-106´ and circulated on SiMSI chips for 2 hr. Chips were then washed and 
incubated with Alexa Fluor 488-labeled goat anti-human IgG (Thermo Scientific) for 30 
min. Chips were washed again and visualized by SiMSI. 
p53 native PAGE and immunoblot. BHK21 cells were transfected using 
Lipofectamine 2000 with mutant or wildtype p53 constructs (0.1-20 µg DNA) in 6-well 
plates. After 16 hr, lysate was prepared with 18 mM CHAPS in TBS containing DNase and 
protease inhibitor. Lysate was added with 20% glycerol and 5 mM Coomassie G-250 dye 
then loaded onto a 3-12% native PAGE Bis-Tris gel (Invitrogen). Electrophoresis was 
performed in 50 mM Bis-Tris and 50 mM Tricine plus 0.02% Coomassie G-250 dye in the 
cathode buffer for 2 hr at 100 V. Proteins were transferred to a polyvinylidene membrane 
and stained with Coomassie G-250 dye. The membrane was fixed with 8% acetic acid for 
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Figure III-1. Single-molecule structural imaging (SiMSI). 
(a) Schematic diagram of the SiMSI platform. Circulating mutant tumor proteins are 
captured on a microfluidic chip and visualized by single-molecule total internal reflection 
fluorescence microscopy. Proteins that score above a set fluorescence threshold are 
digitally counted. By analysis of the spectrum of fluorescence intensities, the structural 
composition of target proteins is determined. (b) Comparison of the detection sensitivity 
of SiMSI and ELISA. For SiMSI, chips conjugated with anti-GFP antibodies were 
incubated with recombinant GFP at various doses. GFP was quantified by single-molecule 




Figure III-1 (continued). Single-molecule structural imaging (SiMSI). (c) Structural 
protein analysis in the sub-fM concentration range. Histograms display the structural 
composition profile of 0.5 fM GFP or background (no GFP). (d) The frequency of GFP 
complexes at 0 or 0.5 fM was quantified. (e-h) SiMSI of cytoplasmic tumor proteins shed 
into the blood. (e) C57BL/6 mice were inoculated with TC-1 tumor cells carrying 
cytoplasmic GFP (CytoGFP) by oropharyngeal or subcutaneous injection. After two 
weeks, serum GFP was measured by SiMSI, and counts for individual mice are shown. (f) 
Tumor formation in athymic mice was induced via delivery of RasG12V and shP53-GFP. 




Figure III-1 (continued). Single-molecule structural imaging (SiMSI). (g) Tumor formation 
in athymic mice was induced via delivery of RasG12V and shP53-GFP. Relationship 
between circulating GFP levels and buccal luminescence in individual naïve, pre-tumor, 
and tumor-bearing mice (n=5 per group). (h) Structural analysis of circulating GFP in 
tumor-bearing mice. Histograms display GFP composition profile in naïve serum or serum 




Figure III-2. Single-molecule imaging of circulating mutant tumor proteins. 
(a-c) Analysis of mutant Ras. (a) Athymic mice were inoculated subcutaneously with 
tumor cells (TC-1) transduced with mutant (RasG12V-GFP, RasG12D-GFP) or wildtype 
(RasWT-GFP) Ras oncogene. Tumor growth kinetics (left) or circulating Ras proteins 
(right) were characterized over time by single-molecule structural imaging (SiMSI). (b, c) 
Single-molecule analysis of Ras nanoclusters in tumor cells. Lysate from RasG12V+ or 
RasWT+ tumor cells was examined by SiMSI. (b) Structural profile of mutant or wildtype 
Ras in tumor cells. (c) The frequency of Ras nanoclusters (>13-mer size) in tumor cells 




Figure III-2 (continued). Single-molecule imaging of circulating mutant tumor proteins. 
(d-f) Analysis of mutant Ras. (d, e) Single-molecule analysis of circulating Ras 
nanoclusters. (d) Representative histograms display structural distribution of circulating 
mutant or wildtype Ras in tumor-bearing mice. (e) The frequency of circulating Ras 
nanoclusters was quantified (*P<0.05, ****P<0.0001). (f) Preferential detection of mutant 
Ras protein. HEK 293 cells were transfected with RasG12V-GFP or RasG12D-GFP. Ras 
proteins were captured and probed with antibodies that specifically recognize either the 




Figure III-2 (continued). Single-molecule imaging of circulating mutant tumor proteins. 
(g, h) Analysis of mutant p53. (g) Comparison of p53 detection sensitivity by SiMSI and 
ELISA. (h) Dual color SiMSI detection of mutant but not wildtype p53. Lysate from 
various tumor cells carrying mutant p53 (CFPAC-1 (C242R), OVCAR3 (R248Q), and 
TOV-112D (R175H)) or cells with wildtype p53 (MCF-7, MCF-10) was probed with 




Figure III-2 (continued). Single-molecule imaging of circulating mutant tumor proteins. 
(i-k) Structural analysis of mutant p53. BHK21 cells transfected with mutant (p53R175H, 
p53L344P) or wildtype (p53WT) p53 linked to GFP were interrogated by SiMSI. (i) 
Histograms display p53 structural profile, depicting the frequency of complexes containing 
indicated copies of p53. (j) The frequency of mutant or wildtype p53 complexes (>10-mer 
size) was quantified (****P<0.0001). (k) Color dot plots display the distribution of mutant 




Figure III-2 (continued). Single-molecule imaging of circulating mutant tumor proteins. 
(l-n) Analysis of mutant p53. (l, m) Single-molecule analysis of mutant p53 shed from 
human cancer cells. Ovarian cancer cells (OVCAR3) were seeded at various densities (103-
105 cells/well). (l) Mutant p53 in filtered supernatant after 24 hr was measured by SiMSI. 
(m) OVCAR3 cells were fractionated into nucleus, cytoplasm, and supernatant. 
Histograms display the structural profile of mutant p53 in each compartment. (n) Kinetics 
of circulating mutant p53 release in a spontaneous tumor model. Tumor formation in 
athymic mice was induced via delivery of RasG12V and human p53R175H. Plots of serum 




Figure III-3. Single-molecule analysis of circulating mutant p53 in cancer patients. 
(a) Standard curve for p53 SiMSI in 50% normal human plasma. (b-d) p53 structural 
analysis in human plasma. BHK21 cells transfected with mutant (p53R175H, p53L344P) or 
wildtype (p53WT) p53 linked to GFP were interrogated by SiMSI. (b) Histograms display 
p53 structural profile, depicting the frequency of complexes containing indicated copies of 
p53. (c) The frequency of mutant or wildtype p53 complexes (>15-mer size) was quantified 
(****P<0.0001; NS, not significant). (d) Color dot plots display the distribution of mutant 




Figure III-3 (continued). Single-molecule analysis of circulating mutant p53 in cancer 
patients. (e) Fluorescence pattern of anti-p53 probe antibodies. Alexa Fluor 555-labeled 
p53 probe antibodies (100 fM) were precipitated on SiMSI chips with anti-isotype IgG. 
Molecule distribution into singlet, doublet, and triplet populations is shown. (f) Linear 
relationship between number of fluorophores per probe and intensity emitted.  (g) Based 






Figure III-3 (continued). Single-molecule analysis of circulating mutant p53 in cancer 
patients. (h-j) Single-molecule analysis of circulating mutant p53 in ovarian cancer. 
Plasma samples from healthy subjects (n=10) or high-grade serous ovarian cancer 
(HGSOC) patients (n=14) were interrogated for mutant p53 by SiMSI. (h) Number of 
circulating p53 complexes was quantified. (i) Structural profile of p53 distribution in two 
HGSOC patients (RG-953, RG-932) and two healthy subjects (55-53445, 22-80971). The 
n values represent the number of data points used for analysis. (j) The amount of p53 




Figure III-3 (continued). Single-molecule analysis of circulating mutant p53 in cancer 
patients. (k) Comparison of detection of anti-p53 autoantibodies by SiMSI or ELISA. (l) 
Circulating anti-p53 autoantibodies in individual subjects were measured by SiMSI. (m) 
Table summarizing complementary analysis of p53 and anti-p53 autoantibodies in HGSOC 




Supplementary Figure III-1. Target molecule concentration via automated closed-loop 
circulation. 
SiMSI chips conjugated with anti-GFP antibody were incubated with GFP for 30 min either 
with or without continuous circulation actuated via a bidirectional syringe pump. Chips 
were visualized by single-molecule imaging and GFP spots were measured. (a) 




Supplementary Figure III-2. Dynamic threshold adjustment to maximize signal/noise 
ratio. 
1 pM p53 or buffer only was added to SiMSI chips and probed with or without anti-p53 
antibodies. (a) The number of fluorescence counts over 500 frames at different threshold 
intensities was digitally counted. (b) The signal/noise ratio for non-specific binding (1 pM 
p53 relative to no p53 in the presence of anti-p53 antibodies) or autofluorescence (1 pM 
p53 relative to no p53 in the absence of anti-p53 antibodies) was calculated at each 
threshold. At threshold values >9,000, the signal/noise ratio for 1 pM p53 detection exceeds 




Supplementary Figure III-3. GFP fluorescence pattern. 
Recombinant GFP (100 fM) was precipitated and examined by SiMSI. (a) Molecule 
distribution into singlet (peak emission: 141 photons) and doublet (peak emission: 246 




Supplementary Figure III-4. Tumor progression kinetics in the spontaneous tumor model 
used to characterize the dynamics of cytoplasmic tumor protein release into blood. 
Tumor formation in athymic mice was induced via injection of RasG12V, shP53-GFP, Sb13 
transposase, and Luciferase cDNA into the buccal mucosa followed by electroporation. 





Supplementary Figure III-5. Kinetics of oncogene-induced release of nucleocytoplasmic 
proteins into the blood. 
Athymic mice received transient delivery of RasG12V and GFP cDNA by injection into the 
buccal mucosa followed by electroporation. Plots depict the amount of serum GFP protein 




Supplementary Figure III-6. Oncogene-induced release of nucleocytoplasmic proteins 
from transformed cells into the blood. 
 (a) Schematic diagram of the experimental design. Normal cells were transformed in vivo 
by oncogene delivery into the buccal mucosa via electroporation. DNA encoding a 
cytoplasmic fluorescence reporter (GFP) as well as a luminescence reporter (luciferase) 
were concurrently administered. Local buccal luminescence imaging was performed one 
day after transgene delivery. Serum was collected at day seven, and GFP levels were 
assessed by SiMSI. (b) Circulating GFP counts in individual mice (n=3) that received 
various combinations of oncogene and GFP reporter (****P<0.0001). (c) Average buccal 




Supplementary Figure III-7. Serum levels of tumor-derived cytoplasmic proteins in a 
spontaneous tumor model as a function of tumor volume. 
Tumor formation in athymic mice was induced via injection of RasG12V, shP53-GFP, Sb13 
transposase, and Luciferase cDNA into the buccal mucosa followed by electroporation. (a) 
Representative photographs of mice with visible tumor (after about seven weeks) or prior 
to the appearance of tumor (‘pre-tumor’). (b) Serum GFP protein or DNA levels were 




Supplementary Figure III-8. Comparison of the stability of GFP protein or DNA in the 
blood. 
Purified GFP protein or DNA was spiked into mouse serum or Tris buffer control and 
incubated at 37°C for the indicated time periods. The amount of protein or DNA remaining 
at each time point was determined by SiMSI or qPCR, respectively. An identical molar 




Supplementary Figure III-9. Native PAGE of mutant and wildtype p53. BHK21 cells were 
transfected with p53WT, p53R175H, or p53L344P cDNA. 
Lysate was prepared, added with 20% glycerol and 5 mM Coomassie G-250 dye, and 
loaded onto a 3-12% native PAGE Bis-Tris gel for electrophoresis. After electrophoresis, 





Supplementary Figure III-10. Immunoblot of mutant and wildtype p53-GFP. 
BHK21 cells were transfected with p53WT-GFP, p53R175H-GFP, or p53L344P-GFP. Lysate 




Supplementary Figure III-11. Distribution of mutant p53 protein shed from tumor cells. 
 (a, b) Conditioned supernatant was collected from human ovarian cancer cells (OVCAR3) 
and passed through a 0.22 µm filter to eliminate debris. Exosomes were isolated by 
ultracentrifugation. The amount of mutant p53 in exosomes or in the corresponding 
supernatant (depleted of exosomes) was measured by single-molecule analysis. 
Unconditioned medium served as a negative control. (a) Mutant p53 levels in exosomes or 




Supplementary Figure III-12. Analysis of mutant p53 organelle distribution in tumor cells 
by SiMSI. 
Human ovarian cancer cells (OVCAR3; p53R248Q) were fractionated into cytoplasm and 
nucleus, and both compartments were probed for p53 with dual N- and C-terminus 
fluorophore-labeled anti-p53 antibodies (clones Y5 and E47, respectively). The frequency 




Supplementary Figure III-13. Kinetics of tumor growth in the spontaneous tumor model 
used to characterize the dynamics of mutant p53 protein release into blood. 
Tumor formation in athymic mice was induced via injection of RasG12V, human p53R175H, 
Sb13 transposase, and Luciferase cDNA into the buccal mucosa followed by 
electroporation. Representative plots of buccal luminescence over time, an index of tumor 




Supplementary Figure III-14. Monitoring distant tumor metastasis in real-time by SiMSI. 
Tumor formation in athymic mice was induced via injection of RasG12V, human p53R175H, 
Sb13 transposase, and Luciferase cDNA into the buccal mucosa followed by 
electroporation. In approximately 20% of mice, peritoneal metastasis is observed. Shown 
is a representative plot from one of these mice, depicting both peritoneal and buccal 
luminescence (blue), as well as serum p53 counts (red). Luminescence serves as an index 




Supplementary Figure III-15. qPCR assay for detection of circulating mutant p53 DNA. 
(a) Standard curve for qPCR detection of mutant p53 DNA. Different amounts of p53R175H 
plasmid DNA (from 20 to 2×106 copies) were subjected to qPCR, and Ct values were 
measured to generate a standard curve (R2=0.9733). The dotted black line indicates the 
assay background in the presence of naïve mouse serum (Ct=31.3). The qPCR assay 
detection limit is 20 copies of p53 DNA. (b) Tumor formation in athymic mice was induced 
via buccal electroporation with RasG12V, human p53R175H, Sb13 transposase, and Luciferase 
(same cohort as in Figure III-2n with individual mice color-coded). Serum p53 DNA at 





Supplementary Figure III-16. Comparison of the stability of p53 protein or DNA in 
serum. 
p53 protein or DNA was spiked into mouse serum and incubated at 37°C for the indicated 
time periods. The amount of p53 protein or DNA remaining at each time point was 
determined by SiMSI or qPCR, respectively. An identical molar amount of protein and 




Supplementary Figure III-17. p53 detection by SiMSI in spiked normal human plasma. 
50% normal human plasma was infused with p53 protein (2 pM) or left untreated and then 
subjected to SiMSI. The p53 signal and non-specific binding levels in human plasma 




Supplementary Figure III-18. Background levels for p53 SiMSI in human plasma. 
Individual plasma samples from a set of 12 randomly chosen human donors were spiked 
with or without p53 protein and subjected to SiMSI. Specific signal (2 pM p53) and non-
specific background (no p53) levels are shown. For analysis of data from ovarian cancer 
patients (Figure III-3g), p53 counts >6 were considered positive. This cutoff corresponds 




Supplementary Figure III-19. Fluorescence distribution of Alexa Fluor 555-labeled p53 
probe antibodies. 
Each color-coded region indicates the frequency of antibodies labeled with one (single), 




Supplementary Figure III-20. Structural analysis of circulating p53 complexes in healthy 
subjects (n=10) and high-grade serous ovarian cancer (HGSOC) patients (n=14). 
Histograms display the frequency of complexes containing the indicated number of protein 
copies. n values denote the number of data points used for each sample analysis. The table 
lists the sample code corresponding to individual study subjects (Figure III-3h, l, m), as 




Supplementary Figure III-21. Assessment of autoantibodies against the N- or C-terminus 
of p53 by SiMSI. 
Biotinylated p53 peptides derived from the N- or C-terminus were synthesized and 
conjugated to SiMSI chips. Plasma from high-grade serous ovarian cancer (HGSOC) 
patients was then passed through the chips and probed with Alexa Fluor 488-labeled anti-
human IgG. The average number of copies of anti-human p53 IgG directed against the N- 
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IV. Chapter 4. Conclusions and future directions 
 
Applications of single-molecule structural imaging to cancer profiling. The 
single-molecule imaging technology we introduced is extremely versatile. Here we 
demonstrated its ability to identify and characterize circulating mutant tumor proteins and 
their associated complexes at a structural level. Notably, the applications of SiMSI are not 
limited to mutant tumor proteins or their autoantibodies. For example, we have found that, 
due to its single-molecule resolution and digital format, SiMSI quantifies conventional 
tumor-associated proteins, such as CA-125 or FOLR, with markedly greater sensitivity and 
accuracy than ELISA. Therefore, this technology holds the potential to transform existing 
clinical cancer biomarker assays. 
We believe the next-generation applications of this technology, however, are even 
more exciting. It is now well-established that mutant oncoproteins and tumor suppressor 
proteins do not act in isolation, but often co-opt entire signaling machineries to mediate 
cancer progression. By direct inference, single-molecule imaging could be employed to 
dissect these signaling machineries within the tumor, for instance from tissue biopsies. 
Intriguingly, we speculate that these machineries may also be shed into the bloodstream, 
where they would be accessible to minimally invasive imaging technology, such as SiMSI. 
Thus, this technology provides the opportunity to decipher the intricate signaling networks 
of tumor cells from a blood sample. This information could identify the presence of cancer, 
help refine a diagnosis, and even point to effective treatment options. 
In order to reach this stage, several key features must be incorporated into the 
SiMSI platform. First, our system is currently capable of tracing up to four unique 
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fluorophore-labeled antibodies at a time, which allows us to visualize four distinct proteins 
in a signaling complex. For instance, in the case of p53, we could design the system to 
reveal not only p53 clusters, but also p53 associated with its binding partners p63, p73, and 
heat-shock proteins. We envision that combinatorial color barcoding schemes could 
exponentially increase the number of unique proteins that could be detected in a single 
complex at one time. 
In addition, we employed a multiplex, parallel channel design in the SiMSI 
microfluidic device, permitting two proteins to be examined in a single sample. As many 
different oncoproteins or tumor suppressor proteins could be altered in malignant cells, 
however, it is desirable to expand the number of mutant proteins that can be interrogated 
simultaneously. To achieve this, the chip could be engineered with a massive number of 
parallel channels segregated from each other via pneumatic valves. Alternatively, capture 
antibodies could be spot-printed rather than infused onto the chip surface. We are currently 
exploring these strategies with the goal of scaling the SiMSI chip up to a high-throughput 
format. We foresee that in the future, proteomic analysis could be conducted by SiMSI to 
characterize a broad panel of oncoproteins, tumor suppressor proteins, transcription 
factors, signaling mediators, and secondary messengers involved in cancer progression, 
and to map out their biochemical interactions. 
Similar analysis could be performed to identify autoantibodies against tumor 
antigens. Though the idea of searching for autoantibodies in serum from cancer patients 
was first conceived long ago, techniques to probe for these autoantibodies have been 
hampered by low sensitivity and potential background contamination. By contrast, SiMSI 
possesses over 1,000 times the sensitivity of these conventional methods and could thus 
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shift the landscape of cancer autoantibodies. It will be intriguing to harness SiMSI in 
proteomic analysis to screen for cancer autoantibodies. 
Applications of single-molecule structural imaging to identify tumor 
neoantigens. Perhaps one of the most exciting applications of SiMSI is in the discovery 
and validation of tumor neoantigens that can be targeted by immunotherapy. We have 
shown that this system is able to identify circulating mutant tumor proteins; these proteins 
comprise a pool within which to look for suitable neoantigens. We are currently building a 
SiMSI platform to functionally screen mutant tumor antigens. In our design, candidate 
mutant epitopes are loaded onto MHC class I proteins conjugated to the chip surface via a 
multimeric scaffold. PBMCs are lysed to solubilize T cell receptors (TCRs), which are then 
infused into the chip. We then probe for TCR occupancy on the mutant peptide-MHC 
(pMHC) proteins, which serves as an index of the number of systemic T lymphocyte 
precursors that recognize the candidate mutant epitopes. We believe that this system may 
evolve into a technology for selecting optimal tumor neoantigens for vaccination. 
Programmed pMHC self-assembly as a powerful technology for vaccination 
against tumor neoantigens. The vaccination technology we introduced, in which pMHC 
polymerization is triggered on the plasma membrane via ANXA5 to drive activation of 
low-affinity cognate T cells, may represent a useful tool to generate immune responses 
against tumor neoantigens. Once the mutant epitopes associated with the greatest TCR 
abundance are elucidated by single-molecule imaging, recombinant DNA techniques can 
be applied to link these epitopes to b2 microglobulin, MHC class I heavy chain, and 
ANXA5 to derive a vaccination platform. While this is a robust process, the synthesis and 
validation of the chimeric protein can be time-consuming. To overcome this hurdle, we 
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propose that a generic ‘empty’ recombinant protein consisting of b2 microglobulin, MHC 
class I heavy chain, and ANXA5 but without peptide fusion can instead be created. This 
protein can then be loaded with mutant tumor epitopes and covalently conjugated at the 
peptide-binding groove. We envision that this type of universal design would allow for 
rapid development of vaccination against many distinct tumor neoantigens. 
Closing remarks. The renaissance of cancer immunotherapy in the 21st century has 
ushered in unprecedented opportunities to control cancer growth in the long term and to 
eradicate metastasis. As we delve deeper into the web of interactions between tumor cells 
and the immune system, signaling pathways and biochemical alterations that can be 
targeted for therapy are being unearthed at breathtaking pace. The discovery that 
endogenous immune responses are naturally directed against mutant tumor antigens 
exemplifies the power of basic science understanding to translate into clinical 
breakthroughs. As the spectrum of possible tumor neoantigens continues to grow and 
methods to modulate the tumor microenvironment become increasingly potent, it is 
essential that we have tools for profiling these mutant tumor antigens and for expanding 
the endogenous lymphocyte populations that recognize them. The technologies we have 
introduced were crafted to achieve this purpose. As these technologies continue to mature, 
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